nach oben

Current Obesity Reports

Erschienen in:

23.05.2019 | Obesity Treatment (CM Apovian, Section Editor)

Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity

verfasst von: Eric Nolen-Doerr, Mary-Catherine Stockman, Ivania Rizo

Erschienen in: Current Obesity Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM).

Recent Findings

GLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1 RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1 RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy.

Summary

GLP-1-based therapies are critical for a patient-centered approach in choosing appropriate pharmacotherapy for T2DM and obesity while also taking into consideration comorbidities, such as cardiovascular and chronic kidney diseases.

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet (London, England). 2011;377(9765):557–67. https://doi.org/10.1016/s0140-6736(10)62037-5.CrossRefPubMedCentral

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2014;384(9945):766–81. https://doi.org/10.1016/s0140-6736(14)60460-8.CrossRef

Zhang N, Yang X, Zhu X, Zhao B, Huang T, Ji Q. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999–2010. J Int Med Res. 2017;45(2):594–609. https://doi.org/10.1177/0300060517693178.CrossRefPubMedPubMedCentral

Fruh SM. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3–S14. https://doi.org/10.1002/2327-6924.12510.CrossRefPubMedPubMedCentral

Seidell JC, Halberstadt J. The global burden of obesity and the challenges of prevention. Ann Nutr Metab. 2015;66(Suppl 2):7–12. https://doi.org/10.1159/000375143.CrossRefPubMed

https://www.cdc.gov/heartdisease/facts.htm. Accessed 03/13 2019.

Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value Health. 2016;19(5):602–13. https://doi.org/10.1016/j.jval.2016.02.008.CrossRefPubMed

Prevention. CfDCa. National Diabetes Statistics Report. Centers for Disease Control and Prevention, US Dept. of Health and Human Services; 2017.

Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–82. https://doi.org/10.1210/jcem-24-10-1076.CrossRefPubMed

10.

Rehfeld JF. The origin and understanding of the incretin concept. Front Endocrinol. 2018;9:387. https://doi.org/10.3389/fendo.2018.00387.CrossRef

11.

White JW, Saunders GF. Structure of the human glucagon gene. Nucleic Acids Res. 1986;14(12):4719–30.CrossRefPubMedPubMedCentral

12.

Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed pharmacother. 2018;108:952–62. https://doi.org/10.1016/j.biopha.2018.08.088.CrossRefPubMed

13.

Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991;87(2):415–23. https://doi.org/10.1172/jci115012.CrossRefPubMedPubMedCentral

14.

Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56(2):117–26. https://doi.org/10.1159/000201231.CrossRefPubMed

15.

Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84(10):3434–8.CrossRefPubMedPubMedCentral

16.

Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–58. https://doi.org/10.1210/en.2003-0323.CrossRefPubMed

17.

Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130(1):159–66. https://doi.org/10.1210/endo.130.1.1309325.CrossRefPubMed

18.

Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes. 1989;38(7):902–5.CrossRefPubMed

19.

Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600–5. https://doi.org/10.1210/endo.141.12.7806.CrossRefPubMed

20.

Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metab Clin Exp. 2014;63(1):9–19. https://doi.org/10.1016/j.metabol.2013.09.010.CrossRefPubMed

21.

Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res. 2010;1350:18–34. https://doi.org/10.1016/j.brainres.2010.03.059.CrossRefPubMedPubMedCentral

22.

Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77(1):257–70.CrossRefPubMed

23.

Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 2001;25(Suppl 5):S42–7. https://doi.org/10.1038/sj.ijo.0801912.CrossRefPubMed

24.

Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes. 1998;47(4):530–7.CrossRefPubMed

25.

Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965–72. https://doi.org/10.1007/s00125-013-2841-0.CrossRefPubMedPubMedCentral

26.

Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabetic Med. 2012;29(5):604–8. https://doi.org/10.1111/j.1464-5491.2011.03496.x.CrossRefPubMed

27.

Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10–8. https://doi.org/10.1007/s00125-010-1896-4.CrossRefPubMed

28.

Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52.CrossRefPubMed

29.

Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52(2):199–207. https://doi.org/10.1007/s00125-008-1195-5.CrossRefPubMed

30.

Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52(2):380–6.CrossRefPubMed

31.

Mari A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsboll T. Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. PLoS One. 2013;8(9):e73154. https://doi.org/10.1371/journal.pone.0073154.CrossRefPubMedPubMedCentral

32.

Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes. 2010;59(5):1117–25. https://doi.org/10.2337/db09-1899.CrossRefPubMedPubMedCentral

33.

Feinle C, Chapman IM, Wishart J, Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides. 2002;23(8):1491–5.CrossRefPubMed

34.

Seimon RV, Brennan IM, Russo A, Little TJ, Jones KL, Standfield S, et al. Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males. Am J Physiol Endocrinol Metab. 2013;304(3):E294–300. https://doi.org/10.1152/ajpendo.00533.2012.CrossRefPubMed

35.

Vazquez Roque MI, Camilleri M, Stephens DA, Jensen MD, Burton DD, Baxter KL, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology. 2006;131(6):1717–24. https://doi.org/10.1053/j.gastro.2006.10.025.CrossRefPubMed

36.

Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25(8):1206–14. https://doi.org/10.1038/sj.ijo.0801655.CrossRefPubMed

37.

Meyer-Gerspach AC, Wolnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, et al. Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav. 2014;129:265–71. https://doi.org/10.1016/j.physbeh.2014.02.043.CrossRefPubMed

38.

Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res. 2004;36(2):111–5. https://doi.org/10.1055/s-2004-814222.CrossRefPubMed

39.

Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab. 2010;95(2):872–8. https://doi.org/10.1210/jc.2009-2054.CrossRefPubMed

40.

Adam TC, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr. 2005;93(6):845–51.CrossRefPubMed

41.

Aulinger BA, Vahl TP, Wilson-Perez HE, Prigeon RL, D'Alessio DA. Beta-cell sensitivity to GLP-1 in healthy humans is variable and proportional to insulin sensitivity. J Clin Endocrinol Metab. 2015;100(6):2489–96. https://doi.org/10.1210/jc.2014-4009.CrossRefPubMedPubMedCentral

42.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36. https://doi.org/10.1111/dom.12849.CrossRefPubMed

43.

Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbol JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60. https://doi.org/10.1016/s2213-8587(17)30013-x.CrossRefPubMed

44.

Ahren B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20(9):2210–9. https://doi.org/10.1111/dom.13353.CrossRefPubMedPubMedCentral

45.

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama. 2015;314(7):687–99. https://doi.org/10.1001/jama.2015.9676.CrossRefPubMed

46.

Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173–5. https://doi.org/10.2337/dc09-1203.CrossRefPubMedPubMedCentral

47.

Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670–8. https://doi.org/10.1210/jc.2008-0115.CrossRefPubMed

48.

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–51. https://doi.org/10.1111/dom.12932.CrossRefPubMedPubMedCentral

49.

Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. https://doi.org/10.7573/dic.212283.CrossRefPubMedPubMedCentral

50.

Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–6.CrossRefPubMed

51.

Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17(9):961–9.CrossRefPubMed

52.

Pandey A, Chawla S, Guchhait P. Type-2 diabetes: current understanding and future perspectives. IUBMB Life. 2015;67(7):506–13. https://doi.org/10.1002/iub.1396.CrossRefPubMed

53.

Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9. https://doi.org/10.1172/jci25102.CrossRefPubMedPubMedCentral

54.

Soukas A, Cohen P, Socci ND, Friedman JM. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 2000;14(8):963–80.PubMedPubMedCentral

55.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808. https://doi.org/10.1172/jci19246.CrossRefPubMedPubMedCentral

56.

Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30. https://doi.org/10.1172/jci19451.CrossRefPubMedPubMedCentral

57.

Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396(6706):77–80. https://doi.org/10.1038/23948.CrossRefPubMed

58.

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science (New York, NY). 1996;271(5249):665–8.CrossRef

59.

Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275(12):9047–54.CrossRefPubMed

60.

Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277(2):1531–7. https://doi.org/10.1074/jbc.M101521200.CrossRefPubMed

61.

Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 1997;272(47):29911–8.CrossRefPubMed

62.

Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–6. https://doi.org/10.1038/nature01137.CrossRefPubMed

63.

Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277(52):50230–6. https://doi.org/10.1074/jbc.M200958200.CrossRefPubMed

64.

Schmitz-Peiffer C. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y Acad Sci. 2002;967:146–57.CrossRefPubMed

65.

Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem. 2002;277(50):48115–21. https://doi.org/10.1074/jbc.M209459200.CrossRefPubMed

66.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(10):Cd006423. https://doi.org/10.1002/14651858.CD006423.pub2.

67.

Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66. https://doi.org/10.1016/s2213-8587(17)30085-2.CrossRefPubMed

68.

Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. https://doi.org/10.1016/j.cmet.2016.06.009.CrossRefPubMed

69.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169(5):631–8.e7. https://doi.org/10.1016/j.ahj.2015.02.002.CrossRefPubMed

70.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

71.

Secrest MH, Udell JA, Filion KB. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017;27(3):194–202. https://doi.org/10.1016/j.tcm.2017.01.009.CrossRefPubMed

72.

• Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141. Randomized double-blind, placebo-controlled trial investigating semaglutide 0.5mg and 1.0mg compared to placebo when added to a patients with T2DM on standard-care regimens. Results indicated that significant reductions in rates of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke were noted in the semaglutide treated groups. CrossRefPubMed

73.

Sposito AC, Berwanger O, de Carvalho LSF, Saraiva JFK. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018;17(1):157. https://doi.org/10.1186/s12933-018-0800-2.CrossRefPubMedPubMedCentral

74.

Higgins V, Adeli K. Postprandial dyslipidemia: pathophysiology and cardiovascular disease risk assessment. EJIFCC. 2017;28(3):168–84.PubMedPubMedCentral

75.

• Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–9. https://doi.org/10.1111/dom.13120. Randomized double-blind, placebo-controlled trial investigating semaglutide 1.0mg versus placebo showing significant post-prandial glucose and lipid improvements in the semaglutide treated group. CrossRefPubMed

76.

• Verges B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab. 2017;43(Suppl 1):2s3–2s12. https://doi.org/10.1016/s1262-3636(17)30067-8. A review article highlighting potential mechanisms for the independent CVD risk reductions observed with GLP-1 RA including effects on blood pressure, lipids, weight loss, blood sugar, and inflammatory marker reduction. CrossRefPubMed

77.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163–72. https://doi.org/10.1111/j.1463-1326.2009.01158.x.CrossRefPubMed

78.

Fu Z, Kuang HY, Hao M, Gao XY, Liu Y, Shao N. Protection of exenatide for retinal ganglion cells with different glucose concentrations. Peptides. 2012;37(1):25–31. https://doi.org/10.1016/j.peptides.2012.06.006.CrossRefPubMed

79.

Dorecka M, Siemianowicz K, Francuz T, Garczorz W, Chyra A, Klych A, et al. Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells. Pharmacol Rep. 2013;65(4):884–90.CrossRefPubMed

80.

Hernandez C, Bogdanov P, Corraliza L, Garcia-Ramirez M, Sola-Adell C, Arranz JA, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172–87. https://doi.org/10.2337/db15-0443.CrossRefPubMed

81.

Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res. 2014;127:104–16. https://doi.org/10.1016/j.exer.2014.05.004.CrossRefPubMed

82.

Shurter A, Genter P, Ouyang D, Ipp E. Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. Diabetes Res Clin Pract. 2013;100(3):362–7. https://doi.org/10.1016/j.diabres.2013.03.018.CrossRefPubMedPubMedCentral

83.

Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381–9. https://doi.org/10.1056/nejm200002103420603.CrossRefPubMed

84.

Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care. 2016;39(7):1089–100. https://doi.org/10.2337/dc16-0024.CrossRef

85.

Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed). 2012;344:d7771. https://doi.org/10.1136/bmj.d7771.CrossRef

86.

Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9(2):95–108. https://doi.org/10.1177/1479164112441526.CrossRefPubMed

87.

Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care. 2014;37(9):2647–59. https://doi.org/10.2337/dc14-1395.CrossRefPubMedPubMedCentral

88.

Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–54. https://doi.org/10.2337/dc10-0482.CrossRefPubMedPubMedCentral

89.

Wenten M, Gaebler JA, Hussein M, Pelletier EM, Smith DB, Girase P, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabetic Med. 2012;29(11):1412–8. https://doi.org/10.1111/j.1464-5491.2012.03652.x.CrossRefPubMed

90.

Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–27. https://doi.org/10.1185/03007990902820519.CrossRefPubMed

91.

Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011;13(6):559–66. https://doi.org/10.1111/j.1463-1326.2011.01376.x.CrossRefPubMed

92.

Steinberg WM, Buse JB, Ghorbani MLM, Orsted DD, Nauck MA. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with Liraglutide: results from the LEADER randomized trial. Diabetes Care. 2017;40(7):966–72. https://doi.org/10.2337/dc16-2747.CrossRefPubMed

93.

Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86. https://doi.org/10.1210/en.2009-1272.CrossRefPubMed

Titel: Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
verfasst von: Eric Nolen-Doerr
Mary-Catherine Stockman
Ivania Rizo
Publikationsdatum: 23.05.2019
Verlag: Springer US
Erschienen in: Current Obesity Reports / Ausgabe 3/2019
Elektronische ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-019-00350-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Extrinsic and Intrinsic Immunometabolism Converge: Perspectives on Future Research and Therapeutic Development for Obesity

Nonalcoholic Fatty Liver Disease and Obesity Treatment

How Group-Based Interventions Can Improve Services for People with Severe Obesity

Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity

Severe Obesity in the Pediatric Population: Current Concepts in Clinical Care

Lessons Learned from the POUNDS Lost Study: Genetic, Metabolic, and Behavioral Factors Affecting Changes in Body Weight, Body Composition, and Cardiometabolic Risk

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin